Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in alpha-mannosidosis

Damme M, Stroobants S, Walkley SU, Lüllmann-Rauch R, D'Hooge R, Fogh J, Saftig P, Lübke T, Blanz J (In Press)
Journal of Neuropathology & Experimental Neurology 70(1): 83-94.

Journal Article | In Press | English

No fulltext has been uploaded

Author
; ; ; ; ; ; ; ;
Publishing Year
ISSN
PUB-ID

Cite this

Damme M, Stroobants S, Walkley SU, et al. Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in alpha-mannosidosis. Journal of Neuropathology & Experimental Neurology. In Press;70(1):83-94.
Damme, M., Stroobants, S., Walkley, S. U., Lüllmann-Rauch, R., D'Hooge, R., Fogh, J., Saftig, P., et al. (In Press). Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in alpha-mannosidosis. Journal of Neuropathology & Experimental Neurology, 70(1), 83-94.
Damme, M., Stroobants, S., Walkley, S. U., Lüllmann-Rauch, R., D'Hooge, R., Fogh, J., Saftig, P., Lübke, T., and Blanz, J. (In Press). Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in alpha-mannosidosis. Journal of Neuropathology & Experimental Neurology 70, 83-94.
Damme, M., et al., In Press. Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in alpha-mannosidosis. Journal of Neuropathology & Experimental Neurology, 70(1), p 83-94.
M. Damme, et al., “Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in alpha-mannosidosis”, Journal of Neuropathology & Experimental Neurology, vol. 70, In Press, pp. 83-94.
Damme, M., Stroobants, S., Walkley, S.U., Lüllmann-Rauch, R., D'Hooge, R., Fogh, J., Saftig, P., Lübke, T., Blanz, J.: Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in alpha-mannosidosis. Journal of Neuropathology & Experimental Neurology. 70, 83-94 (In Press).
Damme, Markus, Stroobants, Stijn, Walkley, Steven U., Lüllmann-Rauch, Renate, D'Hooge, Rudi, Fogh, Jens, Saftig, Paul, Lübke, Torben, and Blanz, Judith. “Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in alpha-mannosidosis”. Journal of Neuropathology & Experimental Neurology 70.1 (In Press): 83-94.
This data publication is cited in the following publications:
This publication cites the following data publications:

9 Citations in Europe PMC

Data provided by Europe PubMed Central.

Chronic enzyme replacement therapy ameliorates neuropathology in alpha-mannosidosis mice.
Damme M, Stroobants S, Ludemann M, Rothaug M, Lullmann-Rauch R, Beck HC, Ericsson A, Andersson C, Fogh J, D'Hooge R, Saftig P, Blanz J., Ann Clin Transl Neurol 2(11), 2015
PMID: 26817023
Fast urinary screening of oligosaccharidoses by MALDI-TOF/TOF mass spectrometry.
Bonesso L, Piraud M, Caruba C, Van Obberghen E, Mengual R, Hinault C., Orphanet J Rare Dis 9(), 2014
PMID: 24502792
Distribution and Severity of Neuropathology in β-Mannosidase-Deficient Mice is Strain Dependent.
Lovell KL, Zhu M, Drummond MC, Switzer RC 3rd, Friderici KH., JIMD Rep 13(), 2014
PMID: 24142277
Natural history of alpha mannosidosis a longitudinal study.
Beck M, Olsen KJ, Wraith JE, Zeman J, Michalski JC, Saftig P, Fogh J, Malm D., Orphanet J Rare Dis 8(), 2013
PMID: 23786919
Increased gait variability in mice with small cerebellar cortex lesions and normal rotarod performance.
Stroobants S, Gantois I, Pooters T, D'Hooge R., Behav. Brain Res. 241(), 2013
PMID: 23219967
Lysosomal dysfunction causes neurodegeneration in mucolipidosis II 'knock-in' mice.
Kollmann K, Damme M, Markmann S, Morelle W, Schweizer M, Hermans-Borgmeyer I, Rochert AK, Pohl S, Lubke T, Michalski JC, Kakela R, Walkley SU, Braulke T., Brain 135(Pt 9), 2012
PMID: 22961545
Arylsulfatase G inactivation causes loss of heparan sulfate 3-O-sulfatase activity and mucopolysaccharidosis in mice.
Kowalewski B, Lamanna WC, Lawrence R, Damme M, Stroobants S, Padva M, Kalus I, Frese MA, Lubke T, Lullmann-Rauch R, D'Hooge R, Esko JD, Dierks T., Proc. Natl. Acad. Sci. U.S.A. 109(26), 2012
PMID: 22689975
Disruption of the autophagy-lysosome pathway is involved in neuropathology of the nclf mouse model of neuronal ceroid lipofuscinosis.
Thelen M, Damme M, Daμμe M, Schweizer M, Hagel C, Wong AM, Cooper JD, Braulke T, Galliciotti G., PLoS ONE 7(4), 2012
PMID: 22536393

54 References

Data provided by Europe PubMed Central.

Early signs of neurolipidosis-related behavioural alterations in a murine model of metachromatic leukodystrophy.
Stroobants S, Leroy T, Eckhardt M, Aerts JM, Berckmans D, D'Hooge R., Behav. Brain Res. 189(2), 2008
PMID: 18336930
Behavioural characterisation of the alpha-mannosidosis guinea pig.
Robinson AJ, Crawley AC, Auclair D, Weston PF, Hirte C, Hemsley KM, Hopwood JJ., Behav. Brain Res. 186(2), 2008
PMID: 17889945
Induction of tolerance to human arylsulfatase A in a mouse model of metachromatic leukodystrophy.
Matzner U, Matthes F, Herbst E, Lullmann-Rauch R, Callaerts-Vegh Z, D'Hooge R, Weigelt C, Eistrup C, Fogh J, Gieselmann V., Mol. Med. 13(9-10), 2007
PMID: 17660863
Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII.
Sands MS, Vogler CA, Ohlemiller KK, Roberts MS, Grubb JH, Levy B, Sly WS., J. Biol. Chem. 276(46), 2001
PMID: 11562370

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 21157375
PubMed | Europe PMC

Search this title in

Google Scholar